IncobotulinumtoxinA (Xeomin) injection for the treatment of spasticity associated with neurological disorders

This page provides the factsheet for the addition of IncobotulinumtoxinA (Xeomin) to MBS item 18360 for the treatment of spasticity associated with neurological disorders.

Page last updated: 08 October 2026

From 1 November 2026, IncobotulinumtoxinA (Xeomin) branded botox will be added to MBS item 18360 for the treatment of moderate to severe focal spasticity associated with a previously diagnosed neurological disorder.

Further information is provided in the Factsheet below:
Word Version - IncobotulinumtoxinA Xeomin injection for the treatment of spasticity associated with neurological disorders.docxWord Version - IncobotulinumtoxinA Xeomin injection for the treatment of spasticity associated with neurological disorders.docx
PDF Version - IncobotulinumtoxinA Xeomin injection for the treatment of spasticity associated with neurological disorders.pdfPDF Version - IncobotulinumtoxinA Xeomin injection for the treatment of spasticity associated with neurological disorders.pdf

In this section